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Take-home message: Few clinically relevant cardiac arrhythmias and no cardiac fatalities 
were observed in patients with MDR-TB treated with bedaquiline and delamanid in Europe 
Dear Editor:  
 
Introduction: 
There is concern that many second line drugs used to treat multidrug-resistant (MDR)- 
tuberculosis (TB) may cause fatal arrhythmias linked to QT interval prolongation. The QT 
interval, measured on an electrocardiogram (ECG), represents the duration of the ventricular 
electrical systole. In order to have a more reproducible value across time and heart rates, the 
QT interval is adjusted according to heart rate (QTc). Fluoroquinolones and, possibly, 
clofazimine can prolong the QTc
1,2
, as do bedaquiline and delamanid.
3,4
 A QTc >500 ms is 
considered a risk factor for ventricular arrhythmias, such as torsades de pointes (TdP).
5 
Overall, 10-20% of patients with drug-induced TdP have genetic predisposition, and >70% 
have at least two other risk factors, like older age, female sex, and electrolyte disturbances.
6 
In smaller cohorts, no cases of fatal arrhythmia have been reported in association with new 
TB drugs; deaths in bedaquiline/delamanid registration trials were not linked to prolonged 
QTc nor arrhythmias.
3,4,7
 The objective of the study was to evaluate the clinical impact of 
QTc prolongation and the number of cardiac events in patients receiving 
bedaquiline/delamanid for MDR-TB treatment in TBnet treatment centres within the World 
Health Organization (WHO) Europe region.  
 
Methods: 
In December 2016, a cross-sectional online survey was distributed to members of the 
Tuberculosis Network European Trialsgroup (TBnet; a Clinical Research Collaboration of the 
European Respiratory Society), and in parallel to a list of TBnet MDR-TB country 
representatives, chosen because of MDR-TB management expertise and previous 
participation in TBnet activities, in 45 countries belonging to the WHO Europe region, 
excluding Central Asia. 
No more than one participant was accepted from each centre; in case of multiple answers 
with differences in content, participants were contacted to confirm the correct answer. 
Participants who reported cardiac events in patients receiving MDR-TB treatment containing 
bedaquiline/delamanid were contacted to obtain additional information. The survey closed in 
July 2017. The questionnaire consisted of: 10 questions on general information and QTc 
prolongation management; 32 questions on treatment experience with bedaquiline/delamanid; 
and 3 questions on the use of the bedaquiline/delamanid combination. The full questionnaire 
is available at: http://tb-
net.org/images/TBnet_completed_projects_QT_survey/TBnet_Survey_on_QT_interval_moni
toring_and_new_TB_drugs.pdf. 
Ethical approval was provided by the Institutional Review Board of Bligny Hospital, France.  
 
Results: 
Overall, 61 valid replies from different hospitals in 41/45 (91%) targeted countries, out of the 
53 included in the WHO Europe region, were retained. The most represented countries were 
Italy (7 participants), Denmark and Spain (4 participants each). Most participants work in 
teaching/university hospitals (49%) and in TB reference hospitals (24%).  
 
Most physicians (50/61: 82%) routinely monitor the QT interval at their centre. Among them, 
22 (44%) perform QT monitoring in all patients undergoing MDR-TB treatment, 20 (40%) 
only in patients receiving new drugs or multiple QT-prolonging drugs, and 8 (16%) do not 
perform it in MDR-TB patients. In MDR-TB patients monitored for QT prolongation, ECGs 
are repeated weekly (23/42: 55%) or monthly (19/42: 45%) during treatment, either before 
administering treatment (34/42: 81%), or 90-120 minutes after administration (8/42: 19%). 
Overall, 34 (68%) of participants use QTc interval, while 16 (32%) use uncorrected QT 
interval. Out of 34 participants measuring QTc, 41% use Fridericia correction (QTcF), 23% 
Bazett correction (QTcB), 18% use both, and 18% did not know which correction was used. 
Most physicians would stop bedaquiline and delamanid in case of prolongation above 500 ms 
(27/61: 44%), or only in case of symptomatic arrhythmias (23/61: 37%); 19% (12/61) would 
also stop the drugs for any prolongation above normal values (470 ms in women, 450 ms in 
men). 
 
Overall, 35 participants (57%) had experience using bedaquiline, and 20 (33%) using 
delamanid. 43% (15/35) and 30% (6/20) of those using bedaquiline and delamanid, 
respectively, require approval from another health body to use the new drug, mainly national 
consiliums. While most physicians used new drugs for no longer than 24 weeks, 26% (9/35) 
and 20% (4/20) had prescribed treatment durations up to 20 months for bedaquiline and 
delamanid, respectively. 
 
Physicians who used bedaquiline had previously treated a limited number of patients with 
this drug (median: 4 patients (interquartile range (IQR): 2-25)). Out of a total of 1044 
bedaquiline-treated patients, this drug had to be stopped in eight cases following QT 
prolongation (0.77%, 95% confidence interval (CI): 0.04%-1.57%). One cardiac event was 
reported (0.10%, 95% CI: 0.01%-0.63%) in a 55-year old diabetic patient from Somalia, 
treated for lymph node MDR-TB, who developed an asymptomatic first-degree 
atrioventricular block associated with QT interval prolongation (QTcF: 460 ms) while 
receiving moxifloxacin, clofazimine, cycloserine, bedaquiline, ethambutol, and 
prothionamide. The QT prolongation was recorded in association with an overdose of 
bedaquiline during the continuation phase of treatment, when the patient took 600 mg daily 
of bedaquiline for 5 days, instead of 200 mg thrice a week, due to a misunderstanding of the 
prescription. The patient was hospitalized and, after 3 weeks, his QTcF normalized and he 
continued bedaquiline until the end of treatment. 
 
Overall, 220 patients were treated with delamanid, with each physician seeing a median of 2 
patients (IQR: 1-13); delamanid was stopped in one case following QT prolongation (0.45%, 
95% CI: 0.02%-2.89%), and one significant cardiac event was reported (0.45%, 95% CI: 
0.02%-2.89%) in a 23-years old female patient from Georgia. The patient, treated for 
pulmonary MDR-TB with delamanid, linezolid, clofazimine, capreomycin, cycloserine, and 
pyrazinamide, and receiving metoprolol, experienced multiple episodes of hypokalaemia and 
concomitant QT prolongation (QTcF>500 ms) with transient palpitations and dyspnoea, but 
no evidence of ECG alterations, which resolved after temporary treatment interruption. 
 
Overall, the use of the new drugs in association with other QT-prolonging drugs was 
common (26/35: 75% with bedaquiline, 18/20: 90% with delamanid), with 29% (10/35) and 
45% (9/20) of physicians reporting to have used bedaquiline and delamanid with two or more 
QT-prolonging drugs. In particular, 24% (14/61) of physicians used the bedaquiline-
delamanid combination in concomitant treatment, and 19% (11/61) sequentially, for a total of 
38 patients exposed to both drugs. 
 
Conclusions: 
QT monitoring during MDR-TB treatment is commonly performed in Europe, although the 
frequency of ECG testing and the management of QT prolongation vary substantially across 
centres and countries. Experience with new drugs still appears to be limited, especially for 
delamanid. Although most participants reported the use the new drugs in association with 
other QT-prolonging agents, bedaquiline and delamanid were stopped in only few cases 
because of QT prolongation. Few clinically relevant cardiac adverse events, and no fatal 
cases, were reported. These findings support published results,
8–10
 and recent data from a 
Phase III clinical trial testing delamanid versus placebo.
11
 In addition, a relevant proportion 
of physicians used new drugs for treatment >6 months
12,13
 and in combination with QT 
interval-prolonging agents.
14,15
 Limitations of this study include retrospective data collection, 
the analysis of aggregate data, incomplete coverage of the WHO Europe region and over-
representation of Western Europe, bias linked to surveys which may lead to underestimating 
the number of events, and the absence of sudden death in the questionnaire. 
 
In conclusion, QTc interval monitoring is regularly performed by physicians treating patients 
with bedaquiline and/or delamanid in WHO Europe region. The frequency of clinically 
relevant cardiac events associated with the use of these drugs is low. Among 1044 patients 
treated with bedaquiline and 220 patients treated with delamanid as part of a MDR-TB 
treatment regimen, not a single case of fatal cardiac event was observed. 
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Table: 
List of countries and centres taking part to the study. 
 
Country N. of 
centers 
Patients 
treated 
with Bdq* 
Patients 
treated 
with Dlm* 
Patients treated 
with Bdq and Dlm 
(concomitant/ 
sequential) 
Patients who had to 
stop a new drug for 
QT prolongation 
(Bdq/Dlm) 
Patients with 
severe cardiac 
events while 
receiving a new 
drug (Bdq/Dlm) 
Albania 1      
Armenia 1 110 46 13 (9/4) 1 (1/0)  
Austria 1 13 1    
Belarus 1 297 33 2 (2/0)   
Belgium 1 7     
Bosnia and 
Herzegovina 
1      
Bulgaria 1      
Croatia 1      
Cyprus 1      
Czech 
Republic 
1      
Denmark 4 9 3 2 (1/1)  1 (1/0) 
Estonia 1 20 13    
Finland 1 3     
France 1 70 12 10 (4/6) 5 (5/0)  
Georgia 1 292 45   1 (0/1) 
Germany 3 39 15 4 (1/3)   
Greece 1   1 (1/0)   
Hungary 1      
Iceland 1      
Ireland 1 2 1 1 (1/0)   
Italy 7 14     
Kosovo 1      
Latvia 1 53 34 4 (0/4)   
Lithuania 1 11 9    
Luxembourg 1 1     
Macedonia 1      
Moldova 1 30   1 (1/0)  
Montenegro 1      
Norway 1      
Poland 1      
Portugal 1 1 1    
Romania 2 40     
Russia 2 13   1 (1/0)  
Serbia 1      
Slovakia 1      
Spain 4      
Sweden 1 4 1    
Switzerland 1 1 1  1 (0/1)  
Netherlands 3 10 4 1 (1/0)   
United 
Kingdom 
3 3 1    
Ukraine 1 1     
Total 61 1044 220 38 (20/18) 9 (8/1) 2 (1/1) 
 
 
